Ocular Therapeutix (OCUL) Notes Payables (2013 - 2023)

Ocular Therapeutix has reported Notes Payables for 9 years, with the latest figure at $2.1 million in Q2 2023.

• For the quarter ending Q2 2023, Notes Payables changed N/A year-over-year to $2.1 million; the trailing twelve-month figure through Jun 2023 stood at $2.1 million (changed N/A YoY), and the FY2020 full-year result was $8.3 million, changed N/A from the prior year.
• Notes Payables for Q2 2023 stood at $2.1 million, down from $8.3 million in the prior quarter.
• The five-year high for Notes Payables was $8.3 million in Q4 2020, with the low at $2.1 million in Q1 2020.
• Average Notes Payables over 3 years is $5.2 million, with a median of $5.2 million recorded in 2020.
• Peak annual rise in Notes Payables reached 299.71% in 2021, while the deepest fall reached 299.71% in 2021.
• Tracing OCUL's Notes Payables over 3 years: stood at $8.3 million in 2020, then changed by 0.0% to $8.3 million in 2021, then sank by 74.87% to $2.1 million in 2023.
• The last three Notes Payables figures came in at $2.1 million (Q2 2023), $8.3 million (Q1 2021), and $8.3 million (Q4 2020), per Business Quant data.

Peer Comparison